Ụlọ ọrụ na-enye 4-Dibuthylamino-2-Hydroxybenzophenone-2-Carboxylic Acid (BBA) CAS 54574-82-2

Anyị na-echekarị ma na-eme ihe kwekọrọ na mgbanwe ọnọdụ gị, wee too.Anyị mgbaru ọsọ na nweta nke a richer mind and body plus the living for Factory Directly ọnọ 4-Dibuthylamino-2-Hydroxybenzophenone-2-Carboxylic Acid (BBA) CAS 54574-82-2, Our intention would be to help customers know their aims .Anyị na-arụ ọrụ dị mma iji nweta nsogbu a na-emeri mmeri ma na-anabata gị n'ezie ịdebanye aha maka anyị.
Anyị na-echekarị ma na-eme ihe kwekọrọ na mgbanwe ọnọdụ gị, wee too.Anyị ebu n'obi na mmezu nke a ọgaranya uche na ahụ tinyere ndị dị ndụ makaChina 4-Dibuthylamino-2-Hydroxybenzophenone na Bba, Anyị nọgidere na-adị elu ọkwa ngwaahịa na ngwọta na Nchikota na anyị magburu onwe tupu ire ahịa na mgbe-sales ọrụ ana achi achi ike asọmpi na-esiwanye globalized ahịa.nabata ndị ahịa ọhụrụ na ndị agadi sitere na ụdị ndụ niile ka ha kpọtụrụ anyị maka mmekọrịta azụmahịa n'ọdịnihu na ihe ịga nke ọma n'otu!

A na-eji 2′-Methoxy-3′-nitro-biphenyl-3-carboxylic acid mee ihe dị ka etiti Eltrombopag.
Eltrombopag, nke GlaxoSmithKline (GSK) mepụtara na UK ma mechaa mebere ya na Novartis na Switzerland, bụ nke mbụ na naanị akwadoro obere molecule na-abụghị peptide TPO agonist n'ụwa.Ndị US FDA kwadoro Eltrombopag na 2008 maka ọgwụgwọ nke idiopathic thrombocytopenic purpura (ITP), na 2014 maka ọgwụgwọ nke anaemia siri ike (AA).Ọ bụkwa ọgwụ izizi nke US FDA kwadoro maka ọgwụgwọ AA n'ime afọ 30 na-adịbeghị anya.
Na december2012, US FDA kwadoro Eltrombopag maka ọgwụgwọ thrombocytopenia na-arịa ọrịa ịba ọcha n'anya C (CHC), nke mere na ndị ọrịa ịba ọcha n'anya C na-arịa ọrịa na-adịghị mma n'ihi ọnụ ọgụgụ platelet dị ala nwere ike ịmalite ma nọgide na-enwe usoro ọgwụgwọ interferon dabeere na ọgwụgwọ maka ọrịa imeju.Na Febụwarị 3,2014, GlaxoSmithKline kwupụtara na FDA nyere ntozu ọgwụgwọ ọgwụgwọ ọgwụgwọ Eltrombopag maka ọgwụgwọ hemopenia na ndị ọrịa nwere nnukwu akwụkwọ kemịkal aplastic anaemia (SAA) bụ ndị na-anabataghị nke ọma na immunotherapy.Na August 24, 2015, US FDA kwadoro Eltrombopag maka ọgwụgwọ thrombocytopenia na ndị okenye na ụmụaka dị afọ 1 na karịa na-adịghị ala ala thrombocytopenia (ITP) ndị na-enweghị nzaghachi zuru oke na corticosteroids, immunoglobulins ma ọ bụ splenectomy.Na Jenụwarị 4, 2018, a kwadoro Eltrombopag ka edepụta ya na China maka ọgwụgwọ nke thrombocytopenia nke mbụ na-alụso ọrịa ọgụ (ITP).

Anyị na-echekarị ma na-eme ihe kwekọrọ na mgbanwe ọnọdụ gị, wee too.Anyị mgbaru ọsọ na nweta nke a richer mind and body plus the living for Factory Directly ọnọ 4-Dibuthylamino-2-Hydroxybenzophenone-2-Carboxylic Acid (BBA) CAS 54574-82-2, Our intention would be to help customers know their aims .Anyị na-arụ ọrụ dị mma iji nweta nsogbu a na-emeri mmeri ma na-anabata gị n'ezie ịdebanye aha maka anyị.
Ụlọ ọrụ na-eweta ozugboChina 4-Dibuthylamino-2-Hydroxybenzophenone na Bba, Anyị nọgidere na-adị elu ọkwa ngwaahịa na ngwọta na Nchikota na anyị magburu onwe tupu ire ahịa na mgbe-sales ọrụ ana achi achi ike asọmpi na-esiwanye globalized ahịa.nabata ndị ahịa ọhụrụ na ndị agadi sitere na ụdị ndụ niile ka ha kpọtụrụ anyị maka mmekọrịta azụmahịa n'ọdịnihu na ihe ịga nke ọma n'otu!